Regulatory hub · UK status
MOTS-c: UK regulatory status
Also known as: Mitochondrial-derived peptide MOTS-c
Last reviewed . Editorial commentary, not legal advice.
AI-friendly summary · MOTS-c
MOTS-c is not a controlled drug and is not scheduled under the Psychoactive Substances Act 2016. It holds no UK marketing authorisation. WADA prohibits MOTS-c under S4.4 (metabolic modulators).
Misuse of Drugs Act 1971
MOTS-c does not appear on any schedule of the Misuse of Drugs Act 1971.
Psychoactive Substances Act 2016
MOTS-c is not covered by the Psychoactive Substances Act 2016.
MHRA and medicines classification
MOTS-c holds no UK marketing authorisation as a medicine. Sold under "research use only" framing.
WADA Prohibited List position
WADA prohibits MOTS-c under S4.4 (metabolic modulators). Prohibited at all times.
ASA advertising framing
UK sellers cannot make longevity, metabolic, or performance claims for MOTS-c in paid advertising. Editorial discussion of the preclinical literature is permitted.
Primary sources
When in doubt about your specific position, consult MHRA directly via the MHRA contact page or seek qualified UK medicines law advice.
Frequently asked questions
Is MOTS-c legal in the UK?
What is the MHRA position on MOTS-c?
Is MOTS-c on the WADA Prohibited List?
What can UK sellers say about MOTS-c in adverts?
Related: MOTS-c editorial entry · UK regulatory hub.